How Long Will the Cannabis Stock Rally Last?

Shares of major cannabis names have surged on hopes of U.S. regulatory relief—Tilray Brands is up ~125% and Curaleaf ~212% over the past six months—after President Trump signed an order reclassifying cannabis to Schedule III. The reclassification should ease medical research, improve banking access and allow normal business expense deductions (lowering effective tax rates for MSOs), which could boost bottom-line results, though interstate commerce remains prohibited. Structural constraints—state-by-state markets forcing vertically integrated supply chains, potential oversupply from new entrants, and persistent illicit markets—mean gains may be transitory; the author expects the rally to extend into next year (2026) but then fade. Tilray currently lacks U.S. cannabis revenue but could enter via hemp operations, and Curaleaf stands to benefit most from tax and banking changes.

Analysis

Market structure: The immediate winners are US-focused multistate operators (MSOs) and banking/ancillary service providers that can immediately claim normal business deductions and improved access to banking; Curaleaf (CURLF) typifies this. Losers include small, undercapitalized single-state operators and the illicit market (which may keep pricing capped), while vertically integrated cost structures remain a barrier to scale because interstate commerce stays banned.

Risk assessment: Tail risks include federal policy reversals, delayed/ambiguous IRS/DOJ guidance (which could negate expected 300–700 bps EBITDA lift), and rapid oversupply driven by Canadian entrants—each could cut equity value by >50%. Time buckets matter: price rallies in days–weeks driven by headlines; fundamental margin relief likely to be realized over 6–12 months; structural normalization (oversupply, price compression) plays out 12–36 months out.

Trade implications: Tactical trades should be event-driven and skew optionality. Favor capital-efficient long exposure to US MSOs that already have state cash flows (CURLF) via equity or 6–12 month call spreads, and use protective puts or collars. Short smaller-cap or pure-export Canadian LP exposure if they announce large US buildouts without clear path to state retail markets.

Contrarian angles: Consensus prices a multi-year re-rating; the market is likely overpricing immediate pan-US benefits and underpricing sustained regulatory/operational friction. Historic parallel: Canadian legalization (2018) produced headline rallies but margin erosion from supply/regs—expect a similar 12–24 month mean reversion. Ancillary winners (payments, labs, real‑estate) may be under-owned and represent lower-risk ways to capture the secular shift.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Curaleaf (CURLF OTC) sized as core US-MSO exposure; protect with a 6–9 month 20% OTM put or a collar; target exit at +30–50% within 6–12 months or tighten if IRS guidance removes tax relief.
• Allocate 0.5–1% to TLRY via 6–9 month call spreads (buy calls vs higher strike) to capture optional upside if Tilray announces rapid US hemp/retail entry; close position on confirmed US license or on a +60% move in TLRY.
• Implement a pair trade: long CURLF 2% vs short TLRY 1–1.5% (net long bias) to capture differential benefit of immediate US deductibility; unwind after 6–12 months or if USD/CAD moves >3% or federal rulemaking clarifies tax treatment.
• Reduce exposure to pure-play small-cap cannabis equities by 50% and purchase 3–6 month put protection on a cannabis ETF/basket (cost target <1% portfolio) to hedge a potential 30–60% downside if oversupply or regulatory setbacks materialize; monitor IRS/DOJ guidance and state-level interstate bills on a rolling 30–90 day cadence.